NCT04184921View on ClinicalTrials.gov

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2024

Conditions

Lung Cancer Non-small Cell Stage IV

Interventions

DRUG

Aspirin 100mg

Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.

DRUG

Osimertinib 80 MG

Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

Trial Locations (1)

400000

Daping Hospital, Chongqing

All Listed Sponsors

lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT04184921 - Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | Biotech Hunter | Biotech Hunter